Survival Benefit after Shifting from Upfront Surgery to Neoadjuvant Treatment in Borderline Resectable Pancreatic Cancer

According to the 2016 National Comprehensive Cancer Network (NCCN) guidelines, patients with borderline resectable pancreatic cancer (BRPC) should receive chemotherapy as the first-line treatment. This study examined the real-world survival benefits of modifying BRPC treatment guidelines. Patients t...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeon, Hyun Jeong, Lim, Soo Yeun, Jeong, HyeJeong, Yoon, So Jeong, Kim, Hongbeom, Shin, Sang Hyun, Heo, Jin Seok, Han, In Woong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10452854/
https://www.ncbi.nlm.nih.gov/pubmed/37626798
http://dx.doi.org/10.3390/biomedicines11082302

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10452854/
https://www.ncbi.nlm.nih.gov/pubmed/37626798
http://dx.doi.org/10.3390/biomedicines11082302

Ejemplares similares